Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

317.97 -3.58 (-1.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 313,521
Open 331.49
Bid (Size) 314.00 (40)
Ask (Size) 319.75 (40)
Prev. Close 321.55
Today's Range 316.54 - 331.49
52wk Range 127.99 - 331.49
Shares Outstanding 22,205,642
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Tech Fund Made a $5.8 Million Bet on an AI Chip Stock Up Nearly 200% Post-IPO ↗
Ambiq Micro designs ultra-low-power chips for wearables, IoT, and edge AI, targeting energy efficiency in connected devices. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance

Performance

YTD
+28.8%
+28.8%
1 Month
+2.5%
+2.5%
3 Month
+26.5%
+26.5%
6 Month
+28.9%
+28.9%
1 Year
+127.7%
+127.7%

More News

Read More
News headline image
This AI Semiconductor Stock Beat the S&P 500 by 9 Points. A Fund Just Exited Completely ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance Stocks
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum ↗
Via Chartmill
Krystal Biotech (NASDAQ:KRYS) Surges After Q1 Beat as VYJUVEK Revenue Hits $116.4M ↗
Via Chartmill
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Krystal (KRYS) Q1 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million? ↗
Via The Motley Fool
Topics Electric Vehicles Regulatory Compliance
News headline image
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals' Empire in Trouble? ↗
Via The Motley Fool
News headline image
Could This Under-the-Radar Healthcare Stock Set You Up for Life? ↗
Via The Motley Fool
News headline image
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
From Palvella Therapeutics Inc.
Via GlobeNewswire
News headline image
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗
Via The Motley Fool
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Krystal Biotech (KRYS) Q4 2025 Earnings Transcript ↗
Via The Motley Fool

Frequently Asked Questions

Is Krystal Biotech, Inc. - Common Stock publicly traded?
Yes, Krystal Biotech, Inc. - Common Stock is publicly traded.
What exchange does Krystal Biotech, Inc. - Common Stock trade on?
Krystal Biotech, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Krystal Biotech, Inc. - Common Stock?
The ticker symbol for Krystal Biotech, Inc. - Common Stock is KRYS on the Nasdaq Stock Market
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 317.97
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 06/12/26 04:00 PM ET
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 7.06B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.